Validation of the quality of life scale: living with HIV

Holzemer, William L.; Spicer, Joan Gygax; Wilson, Holly Skodol; Kemppainen, Jeanne; Coleman, Christopher Lance

doi:10.1046/j.1365-2648.1998.00800.x

Cited by 31 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…48 Questions addressed the presence and frequency of signs and symptoms associated with depression with higher scores indicating the presence of more depressive symptoms (Cronbach ␣ ϭ 0.88-0.90). 49,50 The Living with HIV Scale is a 32-item scale developed by Holzemer et al 51 to measure health-related quality of life in persons with HIV/AIDS based on an earlier study by Wilson et al 52 This scale contains two subscales: a Reverence subscale and a Struggles subscale. Cronbach ␣ reliability was found to be 0.84 by Holzemer et al 51 and 0.83 for this study.…”

Section: Instrumentsmentioning

confidence: 99%

“…49,50 The Living with HIV Scale is a 32-item scale developed by Holzemer et al 51 to measure health-related quality of life in persons with HIV/AIDS based on an earlier study by Wilson et al 52 This scale contains two subscales: a Reverence subscale and a Struggles subscale. Cronbach ␣ reliability was found to be 0.84 by Holzemer et al 51 and 0.83 for this study. 44 The Medical Outcomes Study-Short Form 36, developed by Ware and Sherbourne 53 contains eight subscales that measure physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health.…”

Section: Instrumentsmentioning

confidence: 99%

See 1 more Smart Citation

Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS

Corless

Kirksey

Kemppainen

et al. 2005

AIDS Patient Care and STDs

View full text Add to dashboard Cite

Lipodystrophy-associated manifestations remain a challenge for persons infected with HIV disease and their care providers. Symptomatic HIV disease and side effects of medications are implicated in antiretroviral medication nonadherence. This study examined the relationship between time since initial diagnosis with HIV, presence and type of lipodystrophic symptoms, and adherence to medication regimens in persons with HIV/AIDS. Using a cross-sectional, descriptive design, the sample was composed of 165 persons from three outpatient HIV settings in Boston, Massachusetts; Fresno, California; and Victoria, Texas. Participants completed a questionnaire comprised of sociodemographic questions, adherence scales, quality-of-life scales, and open-ended questions regarding presence and types of lipodystrophy-associated symptoms, and how these physical changes made them feel. Adherence was moderate with a mean score of 1.44 (standard deviation [SD] +/- 1.33) on the Morisky Medication Adherence Scale (MMAS). The MMAS is a Likert-type scale ranging from 0-4, with "0" indicating very adherent. This finding indicated that the participants took their medications moderately well despite self-reports of significant numbers of HIV disease and treatment-related body fat changes. Time since initial diagnosis was 8.86 +/- 5.55 years and was not related to adherence. Nor did the type of lipodystrophic symptoms affect adherence. Quality of life however, was significantly related to adherence suggesting an approach that might be taken to improve adherence.

show abstract

Section: Instrumentsmentioning

confidence: 99%

Section: Instrumentsmentioning

confidence: 99%

Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS

Corless

Kirksey

Kemppainen

et al. 2005

AIDS Patient Care and STDs

View full text Add to dashboard Cite

show abstract

“…Sometimes a diagnosis of AIDS influences the patient's self-perception of what is important for him or her, and surprisingly, some patients experience a better QOL compared with their lives before the disease (Holzemer, Spicer, Wilson, Kemppainen, & Coleman, 1998). In most cases, however, as the QOL worsens with the progression of HIV infection, psychiatric symptoms, including depression and anxiety, are increasingly observed (Campos, Guimarães, & Remien, 2010;Tostes et al, 2004).…”

Section: Introductionmentioning

confidence: 98%

Depression as a major impact on the quality of life of HIV-positive Brazilians

Zimpel

Fleck

2013

Psychology, Health & Medicine

View full text Add to dashboard Cite

Given that mental symptoms might interfere with the quality of life (QOL) of people living with HIV/AIDS (PLHAs), the goal of this paper was to examine the correlation between depression, anxiety, and QOL in a sample of HIV-positive Brazilians. A cross-sectional study was designed to analyze the correlations between the presence of mental symptoms and the QOL scores of PLHAs. Depression and anxiety symptoms were measured using the Beck Depression Inventory and the State-Trait Anxiety Inventory, respectively. The QOL was assessed using the World Health Organization Quality of Life instrument - HIV module. A convenience sample of 308 men and women living with HIV (131 asymptomatic, 91 symptomatic, and 86 with AIDS) in Porto Alegre/RS-Brazil was selected. The depression scores were higher in patients with AIDS compared with asymptomatic and symptomatic patients, yet there were no differences in the anxiety scores between the stages of infection. Better QOL scores were observed in the earlier stages of infection (asymptomatic and symptomatic groups). In the correlation between mental symptoms and QOL scores, the Pearson's coefficient values were of a moderate (r = .47) to a large (r = .65) magnitude for depressive symptoms, and the scores for the anxiety symptoms were small to moderate (r ≤ .35). After adjusting for the disease stage and clinical and sociodemographic variables in a multiple regression model (using QOL as the dependent variable), the depressive symptoms showed significantly higher beta-coefficient values compared with the remaining variables. The data obtained from this study indicate that the QOL of PLHAs is primarily affected by depression. Thus, it has been strongly recommended that treatment programs dedicated to PLHAs assess depressive symptoms, providing subsequent referrals and treatments. Treating depression might be effective for PLHAs and might potentially improve both the overall QOL and the health outcomes.

show abstract

“…[69][70][71] Our ''older'' samples were also relatively young relative to the mean age in traditional aging literature, and the prevalence and clinical correlates of medical co-morbidity and HRQoL may differ as these older HIV infected individuals reach later decades (e.g., 70s and 80s). Moreover, our older HIV + cohorts were mostly Caucasian, which is likely reflective of larger cohort effects evident in the San Diego County HIV epidemic.…”

mentioning

confidence: 99%

Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life

Rodriguez-Penney

Iudicello

Riggs

et al. 2013

AIDS Patient Care and STDs

273

191

View full text Add to dashboard Cite

This study sought to determine the synergistic effects of age and HIV infection on medical co-morbidity burden, along with its clinical correlates and impact on health-related quality of life (HRQoL) across the lifespan in HIV. Participants included 262 individuals across four groups stratified by age (£ 40 and ‡ 50 years) and HIV serostatus. Medical co-morbidity burden was assessed using a modified version of the Charlson Co-morbidity Index (CCI). Multiple regression accounting for potentially confounding demographic, psychiatric, and medical factors revealed an interaction between age and HIV infection on the CCI, with the highest medical co-morbidity burden in the older HIV + cohort. Nearly half of the older HIV + group had at least one major medical comorbidity, with the most prevalent being diabetes (17.8%), syndromic neurocognitive impairment (15.4%), and malignancy (12.2%). Affective distress and detectable plasma viral load were significantly associated with the CCI in the younger and older HIV-infected groups, respectively. Greater co-morbidity burden was uniquely associated with lower physical HRQoL across the lifespan. These findings highlight the prevalence and clinical impact of co-morbidities in older HIV-infected adults and underscore the importance of early detection and treatment efforts that might enhance HIV disease outcomes.

show abstract

Validation of the quality of life scale: living with HIV

Cited by 31 publications

References 11 publications

Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS

Lipodystrophy-Associated Symptoms and Medication Adherence in HIV/AIDS

Depression as a major impact on the quality of life of HIV-positive Brazilians

Co-Morbidities in Persons Infected with HIV: Increased Burden with Older Age and Negative Effects on Health-Related Quality of Life

Contact Info

Product

Resources

About